Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

EULAR 2012: Rewards in Risk Factor Research

  |  Issue: September 2012  |  

Even with the plethora of new therapies, there has not been much improvement in this risk, he said.

“This is still a problem that is very important for all of us,” Dr. Klareskog said. “The major message when we’re talking about comorbidity is that we have a fantastic opportunity here to do something.”

ADVERTISEMENT
SCROLL TO CONTINUE

Thomas Collins is a freelance medical writer based in Florida.

References

  1. Curtis J, Xie F, Chen L, et al. Use of a disease risk score to compare serious infections associated with anti-TNF therapy among high versus lower risk rheumatoid arthritis patients. Arthritis Care Res (Hoboken). 2012 May 3. [Epub ahead of print]
  2. Emery P, Gallo G, Morgan CL, Currie CJ, Poole CD, and Nab H. Evaluation of the association between disease activity and risk of serious infections in subjects with rheumatoid arthritis when treated with etanercept or disease-modifying antirheumatic drugs. Arthritis Rheum. 2011;63:S163.
  3. Demoruelle MK, Weisman MH, Simonian PL, et al. Brief report: Airways abnormalities and rheumatoid arthritis-related autoantibodies in subjects without arthritis: Early injury or initiating site of autoimmunity? Arthritis Rheum. 2012:64;1756-1764.
  4. Hess A, Axmann R, Rech J, et al. Blockade of TNF-α rapidly inhibits pain responses in the central nervous system. Proc Natl Acad Sci USA. 2011;108:3731-3736.
  5. Avina-Zubieta JA, Thomas J, Sadatsafavi M, Lehman AJ, Lacaille D. Risk of incident cardiovascular events in patients with rheumatoid arthritis: A meta-analysis of observational studies. Ann Rheum Dis. 2012 Mar 16. [Epub ahead of print]

Related Articles

    Rheumatology Drugs at a Glance, Part 3: Rheumatoid Arthritis

    Over the past few years, bio­similars and other new drugs have been introduced to treat rheumatic illnesses. Some of the conditions we treat have numerous drug options, others have few or only off-label options. This series, “Rheumatology Drugs at a Glance,” provides streamlined information on the administration of biologic, biosimilar and small molecule inhibitor drugs…

    WindNight / shutterstock.com

    Why & How Our Biologic Drug Discussion with Patients Should Evolve

    As we turn the corner on the second decade of biologic use for rheumatic disorders, a reappraisal of approach in our communication with patients is due. In practice, the impact these agents have on patients’ lives justifies the friction rheumatologists face when connecting patients to them. You can understand why older rheumatologists who apprenticed on…